61% were treated for prostate cancer only, 28% were hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”), 10% were salvage, and 1% were men with BPH only; For ...

Profound Medical Corp. remains rated Sell due to persistent competitive pressures, missed growth promises, and deteriorating financials. PROF's recent 20% stock spike followed news of a Dallas Medical ...

TORONTO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable ...

Profound Medical (PROF) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook ...

- Global medtech leaders, Siemens Healthineers and Cook Medical, shared their common vision with Profound of creating a total diagnostic and interventional MR solution for prostate disease - TORONTO, ...

Profound anticipates total revenue for the fourth quarter of 2024 to be in the approximate range of $4.1 million to $4.2 million, representing year-over-year growth of between 105% and 110%, and ...

Profound Medical PROF shares soared 9.5% in the last trading session to close at $8.34. The move was backed by solid volume ...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Profound Medical Corp. (“Profound” or the “Company”) (NASDAQ: PROF) investors concerning the ...

BOSTON--(BUSINESS WIRE)--AcuityMD, the intelligence platform for the medical technology (MedTech) industry, has been selected by Profound Medical, a medical device company developing customizable, ...

TORONTO, July 31, 2017 (GLOBE NEWSWIRE) -- With reference to its press release dated June 30, 2017, Profound Medical Corp. (TSXV:PRN) (OTCQX:PRFMF) (“Profound”) announced today that all closing ...